加载中
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
常规交易时段
US$85.607
−US$0.403 · -0.47%
盘中时间采用ET。市场数据可能有所延迟。
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
日内区间
当前US$85.607
52周区间
当前US$85.607
盘中时间采用ET。市场数据可能有所延迟。
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
日内区间
当前US$85.607
52周区间
当前US$85.607
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.21亿 USD | 3.37亿 USD | 1.86亿 USD | 7706.2万 USD | 1913.8万 USD |
| 销货成本 | 1.01亿 USD | 8164.3万 USD | 4703.9万 USD | 1237.4万 USD | 190.3万 USD |
| 毛利 | 4.21亿 USD | 2.55亿 USD | 1.39亿 USD | 6468.8万 USD | 1723.5万 USD |
| 研究与开发 | 1.86亿 USD | 1.41亿 USD | 1.03亿 USD | 1.07亿 USD | 1.31亿 USD |
| 销售、一般及管理费用 | 2.57亿 USD | 2.02亿 USD | 1.46亿 USD | 8906.6万 USD | 5922万 USD |
| 营业费用 | 4.43亿 USD | 3.43亿 USD | 2.48亿 USD | 1.96亿 USD | 1.91亿 USD |
| 利息收入 | 1272.7万 USD | 1379.2万 USD | 1373.5万 USD | 385.7万 USD | 36.6万 USD |
| 利息支出 | 1438.9万 USD | 1431.1万 USD | 1510.5万 USD | 1597.9万 USD | 1759万 USD |
| 折旧和摊销 | 2424.4万 USD | 2362.9万 USD | 1082.9万 USD | 323.8万 USD | 97.5万 USD |
| 营业利润 | −2213.6万 USD | −8760.6万 USD | −1.09亿 USD | −1.31亿 USD | −1.73亿 USD |
| 净利润 | −2336.3万 USD | −8794.2万 USD | −1.63亿 USD | −1.36亿 USD | −8398.8万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$149.1
上涨空间 74.17%AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
